Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Venus Concept Inc Stock Price Drops After Direct Offering

Elaine Mendonca by Elaine Mendonca
February 23, 2024
in Breaking News
0
The Rise of Enterprise Business Intelligence Platforms: Transforming Operations in the Healthcare Sector
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Venus Concept, a leader in minimally invasive medical aesthetic and hair restoration technologies, has seen a drop in their stock price following a $1.2 million registered direct offering at $1.465 per share announced on February 23, 2024.

The stock price of Venus Concept Inc. (VERO) on NASDAQ has taken a hit, with after-hours trading showing an 8.60% decrease. The latest price stands at $1.12, reflecting a change of -8.17%.

In 2022, Venus Concept Inc. reported revenue of $99.50 million, marking a decrease from the previous year. Despite the fluctuating stock prices, the company remains committed to developing and delivering cutting-edge technologies to clients worldwide.

VERO Stock Plummets 24.73% on February 23, 2024

On February 23, 2024, VERO stock experienced a significant drop in its price performance. The stock opened at $1.37, which was $0.49 lower than its previous close. Throughout the trading day, VERO shares continued to decline, ending with a price decrease of $0.46. This represented a 24.73% drop in the stock’s value.

VERO Stock Faces Challenges with Declining Financial Performance in 2024

VERO stock had a challenging day on February 23, 2024, as the company’s financial performance took a hit compared to previous periods. According to data from CNN Money, VERO reported a total revenue of $99.50 million for the past year, which represented a 5.8% decrease compared to the previous year. Additionally, the total revenue for the most recent quarter was $17.62 million, showing a 12.25% decrease compared to the previous quarter.

The company’s net income also saw a significant decline, with a reported net loss of $43.70 million for the past year and a net loss of $9.07 million for the most recent quarter. This represented an 89.89% decrease in net income compared to the previous year and a 22.39% decrease compared to the previous quarter.

Earnings per share (EPS) for VERO also took a hit, with an EPS of -$9.94 for the past year and an EPS of -$1.64 for the most recent quarter. This represented a 56.8% decrease in EPS compared to the previous year and a 21.16% decrease compared to the previous quarter.

Overall, VERO’s stock performance on February 23, 2024, reflected the company’s declining financial performance over the past year and quarter. Investors may be concerned about the company’s ability to turn things around and improve its financial results in the future. It will be important for VERO to address the factors contributing to these declines and implement strategies to enhance its revenue and profitability moving forward.

Tags: VERO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Fiscal (1)

Analyst Reaffirms Optimistic View on NICE with Market Outperform Rating

EEFT stock news

Financial Analyst Reaffirms Positive Outlook on Lantheus Holdings

Healthcare cloud based

Analysts Remain Bullish on Evolent Health Adjust Price Targets

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com